Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response

Nature Nanotechnology

Volumn 6, Issue 10, 2011, Pages 645-650

  Li, Haiyan ^a   Li, Yuhuan ^b   Jiao, Jun ^a   Hu, Hong Ming ^b  

^a PORTLAND STATE UNIVERSITY   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINA; ALUMINUM OXIDE; ANTIGENS; DISEASES; MAMMALS; NANOPARTICLES; T-CELLS; TUMORS; VACCINES;

ALPHA ALUMINA; ATTRACTIVE STRATEGIES; AUTOPHAGOSOMES; CANCER PATIENTS; CANCER VACCINE; DENDRITIC CELLS; TUMOUR REGRESSIONS; VACCINE CARRIERS;

CYTOLOGY;

ALPHA ALUMINA NANOPARTICLE; CANCER VACCINE; DRUG CARRIER; NANOPARTICLE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER IMMUNIZATION; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR REGRESSION;

EID: 80455154958     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2011.153     Document Type: Article

References (30)

1. Pardoll, D. M. Cancer vaccines. Nature Med. 4, 525-531 (1998). (Pubitemid 28228086)
2. Finn, O. J. Cancer vaccines: between the idea and the reality. Nature Rev. Immunol. 3, 630-641 (2003). (Pubitemid 37328666)
3. Heath, W. R. & Carbone, F. R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19, 47-64 (2001). (Pubitemid 32368029)
4. Heijst, J. W. J. et al. Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. Science 325, 1265-1269 (2009).
5. Burgdorf, S. & Kurts, C. Endocytosis mechanisms and the cell biology of antigen-presentation. Curr. Opin. Immunol. 20, 89-95 (2008).
6. Vyas, J. M., Van der Veen, A. G. & Ploegh, H. L. The known unknowns of antigen processing and presentation. Nature Rev. Immunol. 8, 607-618 (2008).
7. Cresswell, P., Ackerman, A. L., Giodini, A., Peaper, D. R. & Wearsch, P. A. Mechanisms MHC class I restricted antigen processing and cross-presentation. Immunol. Rev. 207, 145-157 (2005). (Pubitemid 41415014)
8. Guy, B. The perfect mix: recent progress in adjuvant research. Nature Rev. Micro. 5, 505-517 (2007). (Pubitemid 46925379)
9. Pulendran, B. & Ahmed, R. Immunological mechanisms of vaccination. Nature Immunol. 12, 509-517 (2011).
10. Marrack, P., McKee, A. S. & Munks, M. W. Towards an understanding of the adjuvant action of aluminium. Nature Rev. Immunol. 9, 287-293 (2009).
11. Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492-503 (2010).
12. Hermanson, G. T. Bioconjugate Techniques 2nd edn, 1202 (Academic Press, 2008).
13. Matteoni, R. & Kreis, T. E. Translocation and clustering of endosomes and lysosomes depends on microtubules. J. Cell Biol. 105, 1253-1265 (1987). (Pubitemid 18029849)
14. Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R. & Germain, R. N. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6, 715-726 (1997). (Pubitemid 27305734)
15. Regnault, A., et al. Fcg receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189, 371-380 (1999). (Pubitemid 29063258)
16. Kratzer, R., Mauvais, F. X., Burgevin, A., Barilleau, E. & van Endert, P. Fusion proteins for versatile antigen targeting to cell surface receptors reveal differential capacity to prime immune responses. J. Immunol. 184, 6855-6864 (2010).
17. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnol. 25, 1159-1164 (2007). (Pubitemid 47538111)
18. Pelka, K. & Latz, E. Getting closer to the dirty little secret. Immunity 34, 455-458 (2011).
19. Flach, T. L. et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nature Med. 17, 479-487 (2011).
20. Bjørkøy, G. et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on Huntington-induced cell death. J. Cell. Biol. 171. 603-614 (2005). (Pubitemid 41668720)
21. Kirkin, V., McEwan, D. G., Novak, I. & Dikic, I. A role for ubiquitin in selective autophagy. Mol. Cell. 34, 259-269 (2009).
22. Crotzer, V. L. & Blum, J. S. Autophagy and its role in MHC-mediated antigen presentation. J. Immunol. 182, 3335-3341 (2009).
23. Li, Y. H. et al. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 68, 6889-6895 (2008).
24. Uhl, M., et al. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell. Death Differ. 16, 991-1005 (2009).
25. English, L., et al. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nature Immunol. 10, 480-487 (2009).
26. Jagannath, C., et al. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nature Med. 15, 267-276 (2009).
27. Nishida, Y., et al. Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 461, 654-658 (2009).
28. Savina, A., et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 126, 205-218 (2006). (Pubitemid 44026552)
29. de Gruijl, T. D., van den Eertwegh, A. J. M., Pinedo, H. M. & Scheper, R. J. Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines. Cancer Immunol. Immunother. 57, 1569-1577 (2008).
30. Jensen, S. M. et al. Signaling through OX40 enhances antitumor immunity. Semin. Oncol. 37, 524-532 (2010).